TY - JOUR A1 - Aad, G. A1 - Abbott, B. A1 - Abdallah, J. A1 - Abdel Khalek, S. A1 - Abdelalim, A. A. T1 - Search for the Standard Model Higgs boson in the H→WW(⋆)→ℓνℓνH→WW(⋆)→ℓνℓν decay mode with 4.7 fb\(^{−1}\) of ATLAS data at \(\sqrt{s}\)=7 TeV JF - Physics Letters B N2 - A search for the Standard Model Higgs boson in the H→WW(⋆)→ℓνℓνH→WW(⋆)→ℓνℓν (ℓ=e,μℓ=e,μ) decay mode is presented. The search is performed using proton–proton collision data corresponding to an integrated luminosity of 4.7 fb\(^{−1}\) at a centre-of-mass energy of 7 TeV collected during 2011 with the ATLAS detector at the Large Hadron Collider. No significant excess of events over the expected background is observed. An upper bound is placed on the Higgs boson production cross section as a function of its mass. A Standard Model Higgs boson with mass in the range between 133 GeV and 261 GeV is excluded at 95% confidence level, while the expected exclusion range is from 127 GeV to 233 GeV. KW - ATLAS KW - LHC KW - Higgs KW - WW Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-127307 VL - 761 IS - 1 ER - TY - JOUR A1 - Aad, G. A1 - Abbott, B. A1 - Abdallah, J. A1 - Abdelalim, A. A. A1 - Abdesselam, A. T1 - Electron performance measurements with the ATLAS detector using the 2010 LHC proton-proton collision data JF - The European Physical Journal C N2 - Detailed measurements of the electron performance of the ATLAS detector at the LHC are reported, using decays of the Z, W and J/ψ particles. Data collected in 2010 at s√=7 TeV are used, corresponding to an integrated luminosity of almost 40 pb\(^{−1}\). The inter-alignment of the inner detector and the electromagnetic calorimeter, the determination of the electron energy scale and resolution, and the performance in terms of response uniformity and linearity are discussed. The electron identification, reconstruction and trigger efficiencies, as well as the charge misidentification probability, are also presented. KW - electromagnetic calorimeter KW - Atlas detector KW - calorimeter Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-127313 VL - 72 IS - 1909 ER - TY - JOUR A1 - Aad, G. A1 - Abbott, B. A1 - Abdallah, J. A1 - Abdelalim, A. A. A1 - Abdesselam, A. T1 - Performance of the ATLAS Trigger System in 2010 JF - The European Physical Journal C N2 - Proton–proton collisions at √s=7 TeV and heavy ion collisions at \(\sqrt{sNN}\)=2.76 TeV were produced by the LHC and recorded using the ATLAS experiment’s trigger system in 2010. The LHC is designed with a maximum bunch crossing rate of 40 MHz and the ATLAS trigger system is designed to record approximately 200 of these per second. The trigger system selects events by rapidly identifying signatures of muon, electron, photon, tau lepton, jet, and B meson candidates, as well as using global event signatures, such as missing transverse energy. An overview of the ATLAS trigger system, the evolution of the system during 2010 and the performance of the trigger system components and selections based on the 2010 collision data are shown. A brief outline of plans for the trigger system in 2011 is presented. KW - ATLAS KW - Trigger System Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-127321 VL - 72 IS - 1849 ER - TY - JOUR A1 - Aad, G. A1 - Abbott, B. A1 - Abdallah, J. A1 - Abdelalim, A. A. A1 - Abdesselam, A. T1 - Forward-backward correlations and charged-particle azimuthal distributions in pp interactions using the ATLAS detector JF - Journal of High Energy Physics N2 - Using inelastic proton-proton interactions at s√=900 GeV and 7 TeV, recorded by the ATLAS detector at the LHC, measurements have been made of the correlations between forward and backward charged-particle multiplicities and, for the first time, between forward and backward charged-particle summed transverse momentum. In addition, jet-like structure in the events is studied by means of azimuthal distributions of charged particles relative to the charged particle with highest transverse momentum in a selected kinematic region of the event. The results are compared with predictions from tunes of the pythia and herwig++ Monte Carlo generators, which in most cases are found to provide a reasonable description of the data. KW - Hadron-Hadron Scattering Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-127336 VL - 7 IS - 19 ER - TY - JOUR A1 - Abdelmohsen, Usama Ramadan A1 - Szesny, Matthias A1 - Othman, Eman Maher A1 - Schirmeister, Tanja A1 - Grond, Stepanie A1 - Stopper, Helga A1 - Hentschel, Ute T1 - Antioxidant and Anti-Protease Activities of Diazepinomicin from the Sponge-Associated Micromonospora Strain RV115 N2 - Diazepinomicin is a dibenzodiazepine alkaloid with an unusual structure among the known microbial metabolites discovered so far. Diazepinomicin was isolated from the marine sponge-associated strain Micromonospora sp. RV115 and was identified by spectroscopic analysis and by comparison to literature data. In addition to its interesting preclinical broad-spectrum antitumor potential, we report here new antioxidant and anti-protease activities for this compound. Using the ferric reducing antioxidant power (FRAP) assay, a strong antioxidant potential of diazepinomicin was demonstrated. Moreover, diazepinomicin showed a significant antioxidant and protective capacity from genomic damage induced by the reactive oxygen species hydrogen peroxide in human kidney (HK-2) and human promyelocytic (HL-60) cell lines. Additionally, diazepinomicin inhibited the proteases rhodesain and cathepsin L at an IC50 of 70–90 μM. It also showed antiparasitic activity against trypomastigote forms of Trypanosoma brucei with an IC50 of 13.5 μM. These results showed unprecedented antioxidant and anti-protease activities of diazepinomicin, thus further highlighting its potential as a future drug candidate. KW - Biologie KW - diazepinomicin KW - anti-protease KW - antioxidant KW - actinomycetes KW - Micromonospora Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-76279 ER - TY - THES A1 - Adler, Melanie T1 - New approaches to improve prediction of drug-induced liver injury T1 - Neue Ansätze zur verbesserten Vorhersage arzneimittelinduzierter Leberschäden N2 - Das häufige Scheitern neuer Arzneistoffkandidaten aufgrund von Lebertoxizität in präklinischen und klinischen Studien stellt ein erhebliches Problem in der Entwicklung von neuen Arzneimitteln dar. Deshalb ist es wichtig, neue Ansätze zu entwickeln, mit deren Hilfe unerwünschte Wirkungen von Arzneimitteln früher und zuverlässiger erkannt werden können. Um die Vorhersage von Lebertoxizität in präklinischen Studien zu verbessern, wurden im Rahmen dieser Arbeit zwei wesentliche Ansätze gewählt: 1) die Evaluierung neuer Biomarker, durch die Lebertoxizität zuverlässiger und empfindlicher detektiert werden könnte und 2.) wirkmechanistische Untersuchungen mittels Toxcicogenomics für ein besseres Verständnis der zugrunde liegenden Mechanismen der Arzneimittel-induzierten Toxizität. Ein Ziel dieser Arbeit war, die Fähigkeit einiger neuer potenzieller Biomarker (NGAL, Thiostatin, Clusterin und PON1) zu bewerten, Arzmeimittel-induzierte Lebertoxizität in Ratten frühzeitig zu erkennen. Die Ergebnisse zeigen, dass PON1 und Clusterin infolge eines durch die verabreichten Arzneistoffkandidaten verursachten Leberschadens nicht konsistent verändert waren. Diese beiden Marker sind daher, verglichen mit bestehenden klinisch-chemischen Markern, nicht für eine sichere Vorhersage von Arzneistoff-induzierten Leberschäden geeignet. Bei Thiostatin und NGAL zeigte sich hingegen ein zeit- und dosisabhängiger Anstieg im Serum und Urin behandelter Tiere. Diese Veränderungen, die gut mit der mRNA Expression im Zielorgan übereinstimmten, korrelierten mit dem Schweregrad der Arzneistoff-induzierten Leberschäden. Die Analyse mittels ROC zeigte, Thiostatin im Serum, nicht aber NGAL, ein besserer Indikator für Arzneimittel-induzierte hepatobiliäre Schäden ist als die routinemäßig verwendeten klinische-chemischen Marker, wie z.B. die Leberenzyme ALP, ALT und AST. Thiostatin wird jedoch als Akute-Phase-Protein in einer Vielzahl von Geweben exprimiert und kann somit nicht spezifisch als Lebermarker betrachtet werden. Dennoch zeigen unsere Ergebnisse, dass Thiostatin als sensitiver, minimal-invasiver diagnostischer Marker für Entzündungsprozesse und Gewebeschäden eine sinnvolle Ergänzung in der präklinischen Testung auf Lebertoxizität darstellt. Im zweiten Teil dieser Arbeit wurde mittels RNA-Interferenz das pharmakologische Target des Arzneistoffkandidaten BAY16, der Glukagonrezeptor, auf mRNA-Ebene gehemmt und anhand von Genexpressionsanalysen untersucht, ob die pharmakologisch-bedingte Modulation des Glukagonrezeptors eine Rolle in der Toxizität von BAY16 spielt. Desweiteren sollten diese Arbeiten Aufschluss geben, welche molekularen Veränderungen auf die pharmakologische Wirkung des Arzneistoffs zurückzuführen sind, und daher für den Mechanismus der Toxizität möglicherweise wenig relevant sind. Während BAY16 in Konzentrationen von 75 µM starke zytotoxische Wirkungen aufwies, hatte die siRNA vermittelte Depletion des Glukagonrezeptors keinen Einfluss auf die Vitalität primärer Rattenhepatozyten. Daraus lässt sich ableiten, dass die Hepatotoxiziät von BAY16 in vitro und in vivo nicht mit der pharmakologischen Modulation des Glukagonrezeptors assoziiert ist. Diese Ergebnisse wurden durch die Tatsache gestützt, dass die meisten der durch BAY16 induzierten Genexpressionsveränderungen unabhängig von der pharmakologischen Modulation des Glucagonrezeptors auftraten. Diese beobachteten off-target-Effekte beinhalteten Veränderungen im Fremdstoffmetabolismus, oxidativer Stress, erhöhte Fettsäuresynthese und Veränderungen im Cholesterol- und Gallensäuremetabolismus. Obwohl Veränderungen in diesen molekularen Mechanismen zum Fortschreiten eines Leberschadens beitragen können, ist es anhand dieser Daten nicht möglich einen eindeutigen Mechanismus für die Toxizität von BAY16 abzuleiten. In dieser Arbeit konnte jedoch gezeigt werden, dass die Anwendung der siRNA-Technologie einen neuen methodischen Ansatz darstellt, um Mechanismen arzneimittelbedingter Toxizität besser verstehen zu können. N2 - The high failure rate of new drug candidates in preclinical or clinical studies due to hepatotoxicity represents a considerable problem in the drug development. Hence, there is an urgent need to develop new approaches for early and reliable prediction of drug-induced hepatotoxicity that enables a better identification of drug candidates with high potential for toxicity at early stages of drug development. Therefore, the aim of this work was to improve the prediction of drug-induced liver injury in preclinical studies through evaluation of more reliable and sensitive biomarkers of hepatotoxicity and a better understanding of the underlying mechanistic basis for drug-induced toxicity. First, the ability of a set of potential markers (NGAL, thiostatin, clusterin, PON1) to detect early signs of liver injury was assessed in rats treated with drug candidates that were dropped from further development, in part due to toxic adverse effects in the liver. In summary, PON1 and clusterin were not consistently altered in response to liver injury and thus provide no additive information to the traditional liver enzymes in detecting drug-induced hepatotoxicity. In contrast, thiostatin and NGAL were increased in serum and urine of treated animals in a time- and dose-dependent manner. These changes correlated well with mRNA expression in the target organ and generally reflected the onset and degree of drug-induced liver injury. Receiver-operating characteristics analyses supported serum thiostatin, but not NGAL, as a better indicator of drug-induced hepatobiliary injury than conventional clinical chemistry parameters, such as ALP, ALT and AST. Although thiostatin, an acute phase protein expressed in a range of tissues, may not be specific for liver injury, our results indicate that thiostatin may serve as a sensitive, minimally-invasive diagnostic marker of inflammation and tissue damage in preclinical safety assessment. In the second part of this work, combined application of genomics profiling technology and RNAi to inhibit the pharmacological target of a drug candidate BAY16, a glucagon receptor (GCGR) antagonist, was used to determine if interference with the pharmacological target plays a role in the toxic response to BAY16, and to narrow down those molecular changes that are associated with toxicity, and not the pharmacological action of BAY16. In contrast to Bay 16, which was found to be cytotoxic at concentrations of 75 µM, silencing of the glucagon receptor did not affect cell viability in primary rat hepatocytes. Thus, it can be concluded that hepatotoxicity of Bay 16 was not related to the drugs inhibitory effect on the glucagon receptor in vitro and in vivo. These findings were supported by the fact that most of BAY16-induced changes in gene expression occurred independently of the pharmacological modulation of GCGR. These off-target effects include altered xenobiotic metabolism, oxidative stress, increased fatty acid synthesis, and alterations in cholesterol and bile acid metabolic processes. Although it was not possible to draw a final conclusion about the mechanism of BAY16 hepatotoxicity, changes in these molecular mechanisms appear contribute to progression of hepatic injury. With regard to drug safety assessment in preclinical studies, the utilization of siRNA technology in vitro represents a new approach to improve mechanistic understanding of the nature of drug’s toxicity, being either chemically mediated or due to primary or secondary pharmacological mode of action. KW - Biomarker KW - Leber KW - Hepatotoxizität KW - Lebertoxizität KW - biomarker KW - liver KW - hepatotoxicity Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-69512 ER - TY - JOUR A1 - Aeschlimann, Martin A1 - Bauer, Michael A1 - Bayer, Daniela A1 - Brixner, Tobias A1 - Cunovic, Stefan A1 - Fischer, Alexander A1 - Melchior, Pascal A1 - Pfeiffer, Walter A1 - Rohmer, Martin A1 - Schneider, Christian A1 - Strüber, Christian A1 - Tuchscherer, Philip A1 - Voronine, Dimitri V. T1 - Optimal open-loop near-field control of plasmonic nanostructures N2 - Optimal open-loop control, i.e. the application of an analytically derived control rule, is demonstrated for nanooptical excitations using polarization-shaped laser pulses. Optimal spatial near-field localization in gold nanoprisms and excitation switching is realized by applying a shift to the relative phase of the two polarization components. The achieved near-field switching confirms theoretical predictions, proves the applicability of predefined control rules in nanooptical light–matter interaction and reveals local mode interference to be an important control mechanism. KW - Chemie Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-75256 ER - TY - JOUR A1 - Agoston, Zsuzsa A1 - Li, Naixin A1 - Haslinger, Anja A1 - Wizenmann, Andrea A1 - Schulte, Dorothea T1 - Genetic and physical interaction of Meis2, Pax3 and Pax7 during dorsal midbrain development JF - BMC Developmental Biology N2 - Background: During early stages of brain development, secreted molecules, components of intracellular signaling pathways and transcriptional regulators act in positive and negative feed-back or feed-forward loops at the mid-hindbrain boundary. These genetic interactions are of central importance for the specification and subsequent development of the adjacent mid-and hindbrain. Much less, however, is known about the regulatory relationship and functional interaction of molecules that are expressed in the tectal anlage after tectal fate specification has taken place and tectal development has commenced. Results: Here, we provide experimental evidence for reciprocal regulation and subsequent cooperation of the paired-type transcription factors Pax3, Pax7 and the TALE-homeodomain protein Meis2 in the tectal anlage. Using in ovo electroporation of the mesencephalic vesicle of chick embryos we show that (i) Pax3 and Pax7 mutually regulate each other's expression in the mesencephalic vesicle, (ii) Meis2 acts downstream of Pax3/7 and requires balanced expression levels of both proteins, and (iii) Meis2 physically interacts with Pax3 and Pax7. These results extend our previous observation that Meis2 cooperates with Otx2 in tectal development to include Pax3 and Pax7 as Meis2 interacting proteins in the tectal anlage. Conclusion: The results described here suggest a model in which interdependent regulatory loops involving Pax3 and Pax7 in the dorsal mesencephalic vesicle modulate Meis2 expression. Physical interaction with Meis2 may then confer tectal specificity to a wide range of otherwise broadly expressed transcriptional regulators, including Otx2, Pax3 and Pax7. KW - dosage KW - quali-chick chimeras KW - drosophila embryo KW - neural crest KW - transcription activation KW - hindbrain boundary KW - isthmic oragnizer KW - sonic hedghog KW - expression KW - induction Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-132626 VL - 12 IS - 10 ER - TY - THES A1 - Ahmad, Ruhel T1 - Neurogenesis from parthenogenetic human embryonic stem cells T1 - Neurogenese von parthenogenetischen humanen embryonalen Stammzellen N2 - Imprinted genes play important roles in brain development. As the neural developmental capabilities of human parthenogenetic embryonic stem cells (hpESCs) with only a maternal genome were not assessed in great detail, hence here the potential of hpESCs to differentiate into various neural subtypes was determined. In addition DNA methylation and expression of imprinted genes upon neural differentiation was also investigated. The results demonstrated that hpESC-derived neural stem cells (hpNSCs) showed expression of NSC markers Sox1, Nestin, Pax6, and Musashi1 (MS1), the silencing of pluripotency genes (Oct4, Nanog) and the absence of activation of neural crest (Snai2, FoxD3) and mesodermal (Acta1) markers. Moreover, confocal images of hpNSC cultures exhibited ubiquitous expression of NSC markers Nestin, Sox1, Sox2 and Vimentin. Differentiating hpNSCs for 28 days generated neural subtypes with neural cell type-specific morphology and expression of neuronal and glial markers, including Tuj1, NeuN, Map2, GFAP, O4, Tau, Synapsin1 and GABA. hpNSCs also responded to region-specific differentiation signals and differentiated into regional phenotypes such as midbrain dopaminergic- and motoneuron-type cells. hpESC-derived neurons showed typical neuronal Na+/K+ currents in voltage clamp mode, elicited multiple action potentials with a maximum frequency of 30 Hz. Cell depicted a typical neuron-like current pattern that responded to selective pharmacological blockers of sodium (tetrodotoxin) and potassium (tetraethylammonium) channels. Furthermore, in hpESCs and hpNSCs the majority of CpGs of the differentially methylated regions (DMRs) KvDMR1 were methylated whereas DMR1 (H19/Igf2 locus) showed partial or complete absence of CpG methylation, which is consistent with a parthenogenetic (PG) origin. Upon differentiation parent-of-origin-specific gene expression was maintained in hpESCs and hpNSCs as demonstrated by imprinted gene expression analyses. Together this shows that despite the lack of a paternal genome, hpNSCs are proficient in differentiating into glial- and neuron-type cells, which exhibit electrical activity similar to newly formed neurons. Moreover, maternal-specific gene expression and imprinting-specific DNA-methylation are largely maintained upon neural differentiation. hpESCs are a means to generate histocompatible and disease allele-free ESCs. Additionally, hpESCs are a unique model to study the influence of imprinting on neurogenesis. N2 - Imprinted Gene spielen eine wichtige Rolle bei der Gehirnentwicklung. Da das neurale Entwicklungspotenzial von hpESCs bisher noch nicht ausführlich untersucht wurde, war das Ziel dieser Arbeit das Differenzierungspotenzial von hpESCs zu verschiedenen neuralen Subtypen zu untersuchen. Außerdem wurden die DNA-Methylierung und Expression imprinted Gene in hpESCs während der neuralen Differenzierung analysiert. Die Ergebnisse zeigten, dass von hpESCs abgeleitete neurale Stammzellen (hpNSCs) die NSC-Marker Sox1, Nestin, Pax6 und Musashi1 (MS1) exprimierten, Pluripotenzmarker-Gene (Oct4, Nanog) abschalteten und keine Aktivierung von Markern der Neuralleistenzellen (Snai2, FoxD3) sowie dem mesodermalen Marker Acta1 stattfand. Immunfärbungen zeigten weiterhin, dass aus hpESCs abgeleitete Stammzellen die NSC-Marker Nestin, Sox1, Sox2 und Vimentin auf Proteinebene exprimierten. Durch gerichtete neurale Differenzierung für 28 Tage konnten aus hpESCs neurale Subtypen abgeleitet werden, die eine neurale Zelltyp-spezifische Morphologie aufweisen und positiv für neuronale und gliale Marker wie Tuj1, NeuN, Map2, GFAP, O4, Tau, Synapsin1 und GABA sind. Um aus hpNSCs dopaminerge und Motoneuronen abzuleiten, wurden während der Differenzierung Morphogene und trophische Faktoren zugegeben. Elektrophysiologische Analysen konnten zeigen, dass die in vitro differenzierten Neuronen, die von hpESCs abgeleitet wurden, für Neurone typische Na+/K+ Ströme sowie Aktionspotentiale (30 Hz) vorweisen ausbilden und auf ausgewählte pharmakologische Natrium- (Tetrodotoxin) und Kalium- (Tetraethylammonium) Kanal-Blocker reagierten. Desweiteren war der Großteil der CpGs von differentiell methylierten Regionen (DMRs) KvDMR1 in hpESCs und hpNSCs methyliert, während DMR1 (H19/Igf2 Locus) eine partiell oder komplett abwesende CpG-Methylierung zeigte, was dem parthenogenetischen Ursprung entspricht. Während der Differenzierung wurde die elternabhängige (parent-of-origin) spezifische Genexpression in hpESCs und hpNSCs aufrechterhalten, wie mit Genexpressionsanalysen imprinted Gene gezeigt werden konnte. In der Summe zeigen die hier dargestellten Ergebnisse, dass hpESCs, die kein paternales Genom besitzen, keine Beeinträchtigung im neuralen Differenzierungspotential zeigten und zu Gliazellen und Neurone differenziert werden konnten. Elektrophysiologische Analysen zeigten ferner, dass von hpESCs abgeleitete Neurone funktionell sind. Zudem wird die Expression maternal-spezifischer Gene und die Imprinting-spezifische DNA-Methylierung während der Differenzierung größtenteils aufrechterhalten. In der Summe stellen hpESCs ein einzigartiges Modell dar, um den Einfluss des Imprintings auf die Neurogenese zu untersuchen. KW - Embryonale Stammzelle KW - Neurogenese KW - Zelldifferenzierung KW - Stammzelle KW - human parthenogenetic stem cells KW - in vitro neural differentiation KW - human parthenogenetic neural stem cells KW - PG neurons KW - imprinting. Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-75935 ER - TY - JOUR A1 - Ahmad, Ruhel A1 - Wolber, Wanja A1 - Eckardt, Sigrid A1 - Koch, Philipp A1 - Schmitt, Jessica A1 - Semechkin, Ruslan A1 - Geis, Christian A1 - Heckmann, Manfred A1 - Brüstle, Oliver A1 - McLaughlin, John K. A1 - Sirén, Anna-Leena A1 - Müller, Albrecht M. T1 - Functional Neuronal Cells Generated by Human Parthenogenetic Stem Cells JF - PLoS One N2 - Parent of origin imprints on the genome have been implicated in the regulation of neural cell type differentiation. The ability of human parthenogenetic (PG) embryonic stem cells (hpESCs) to undergo neural lineage and cell type-specific differentiation is undefined. We determined the potential of hpESCs to differentiate into various neural subtypes. Concurrently, we examined DNA methylation and expression status of imprinted genes. Under culture conditions promoting neural differentiation, hpESC-derived neural stem cells (hpNSCs) gave rise to glia and neuron-like cells that expressed subtype-specific markers and generated action potentials. Analysis of imprinting in hpESCs and in hpNSCs revealed that maternal-specific gene expression patterns and imprinting marks were generally maintained in PG cells upon differentiation. Our results demonstrate that despite the lack of a paternal genome, hpESCs generate proliferating NSCs that are capable of differentiation into physiologically functional neuron-like cells and maintain allele-specific expression of imprinted genes. Thus, hpESCs can serve as a model to study the role of maternal and paternal genomes in neural development and to better understand imprinting-associated brain diseases. KW - methylation KW - derivation KW - blastocysts KW - pluripotent KW - differentiation KW - lines KW - brain development KW - in-vitro KW - mice KW - specification Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-130268 VL - 7 IS - 8 ER -